Moderna (MRNA) anticipates milestones across 10 prioritized programs, including up to three potential 2025 approvals and six registrational data readouts.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRNA:
- Moderna sees FY25 revenue $1.5B-$2.5B, consensus $2.94B
- Is There an Opportunity in Moderna Stock’s Volatility?
- Biotech Alert: Searches spiking for these stocks today
- Trump Trade: New administration to invest $20B to build data centers
- Wall Street’s Best and Worst Performers of 2025: Week 1